SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
Turning Point Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|(State of incorporation or organization)||(I.R.S. Employer Identification No.)|
10628 Science Center Drive, Ste. 225
San Diego, California
|(Address of principal executive offices)||(Zip Code)|
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class
Name of exchange on which
|Common Stock, $0.0001 par value per share||The Nasdaq Stock Market LLC|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement file number to which the form relates:
Securities to be registered pursuant to Section 12(g) of the Act:
(Title of class)
|Item 1.|| |
Description of Registrants Securities to be Registered.
A description of the common stock, $0.0001 par value per share, of Turning Point Therapeutics, Inc., a Delaware corporation (the Registrant), to be registered hereunder is contained in the section entitled Description of Capital Stock in the prospectus included in the Registrants Registration Statement on Form S-1 (File No. 333-230428), initially filed with the Securities and Exchange Commission (the Commission) on March 21, 2019, as subsequently amended (the Registration Statement), and is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.
|Item 2.|| |
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
|Turning Point Therapeutics, Inc.|
|Date: April 15, 2019||By:|
Athena Countouriotis, M.D.
President and Chief Executive Officer
Turning Point Therapeutics is now a
Bristol Myers Squibb company
Select OK for information about Turning Point Therapeutics.
Select BMS to learn more about Bristol Myers Squibb